Quick Answer
Evofem Biosciences, Inc. reported R&D Expense of $1.84 million for fiscal year 2024.
Evofem Biosciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $1.84M | -37.2% |
| 2023 | $2.94M | -88.3% |
| 2022 | $25.03M | -24.4% |
| 2021 | $33.13M | +94.3% |
| 2020 | $17.05M | -23.3% |
| 2019 | $22.23M | -48.8% |
| 2018 | $43.41M | +84.4% |
| 2017 | $23.54M | +257.8% |
| 2016 | $6.58M | -80.9% |
| 2015 | $34.41M | +564.9% |
| 2014 | $5.17M | -54.8% |
| 2013 | $11.45M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $332.0K | -45.9% | +23.0% |
| June 30, 2024 | $270.0K | -32.8% | -54.5% |
| March 31, 2024 | $594.0K | +10.0% | -3.3% |
| September 30, 2023 | $614.0K | -88.2% | +52.7% |
| June 30, 2023 | $402.0K | -94.8% | -25.6% |
| March 31, 2023 | $540.0K | -94.8% | -89.6% |
| September 30, 2022 | $5.21M | -40.2% | -32.8% |
| June 30, 2022 | $7.74M | -9.0% | -25.5% |
- Evofem Biosciences, Inc. showed a decrease of -37.2% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2024 period, Evofem Biosciences, Inc.’s r&d expense has declined by 83.9% (from $11.45 million to $1.84 million).
- The most recent figure is from Evofem Biosciences, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: